Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
27 hedge funds and large institutions have $88.9M invested in Alpine Immune Sciences Inc in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
13% more funds holding
Funds holding: 24 → 27 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $91M → $88.9M (-$2.15M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$463K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$218K |
| 3 |
Millennium Management
New York
|
+$199K |
| 4 |
Renaissance Technologies
New York
|
+$169K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$128K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$218K |
| 2 |
SIM
Spark Investment Management
New York
|
-$151K |
| 3 |
VF
Virtu Financial
New York
|
-$148K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$53.7K |
| 5 |
JP Morgan Chase
New York
|
-$30K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Macquarie Group
Sydney, NSW 2000,
Australia
| $8K | +$7.62K | +700 | New |
|
|
PWM
27
Perigon Wealth Management
San Francisco,
California
| $2K | – | – | – |
|
|
VF
28
Virtu Financial
New York
| – | -$148K | -12,791 | Closed |
|
|
29
JP Morgan Chase
New York
| – | -$30K | -2,600 | Closed |
|
30
Acadian Asset Management
Boston,
Massachusetts
| – | -$26K | -2,265 | Closed |
|
ALPN Hedge Fund Activity: Q4 2017 in Review
27 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q4 2017, worth a combined $88.9M — down 2.4% from $91M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ALPN positions and 4 closed out — a net gain of 3 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $463K. The largest seller was Deerfield Management, cutting an estimated $218K.
- 27 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q4 2017, up from 24 in Q3 2017.
- Funds reported $88.9M of Alpine Immune Sciences Inc stock for Q4 2017, down 2.4% quarter-over-quarter.
- 7 funds opened new Alpine Immune Sciences Inc positions in Q4 2017 and 4 closed out, a net change of +3 holders.
- The largest Alpine Immune Sciences Inc buyer in Q4 2017 was Vanguard Group, an estimated $463K added.
- The largest Alpine Immune Sciences Inc seller in Q4 2017 was Deerfield Management, an estimated $218K sold.
Based on aggregated 13F filings for Q4 2017.